Qun (Max) Dang

Asia Head–External Innovation, Endo & CV Research Eli Lilly and Company (China)

Qun (Max) DangDr. Qun (Max) Dang, Asia Head–External Innovation, Endo & CV Research at Eli Lilly and Company.
Max joined Gensia pharmaceuticals (later became Metabasis) in 1992 and worked until 2009 with his last position as director of medicinal chemistry. During his time at Metabasis, Max managed multiple drug discovery projects primarily in metabolic disease areas such as diabetes and dyslipidemia (such as FBPase inhibitors, glucagon antagonists, glucokinase activators, and AMPK activators). Since joining Merck in 2009, Max managed several integrated drug discovery projects carried out at various CROs in the areas of diabetes, infectious disease and endocrine related diseases. His teams delivered multiple PCCs for HIV, HCV, diabetes, and Alzheimer’s disease. His research interests include medicinal chemistry via rational drug design, heterocyclic chemistry, prodrugs, and nucleoside chemistry. Dr. Dang has authored or co-authored 87 publications in peer-reviewed journals, 2 book chapters, and 60 granted patents and applications.